Mikkael A. Sekeres (Author)
Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA's cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient advocacy, for the government to take responsibility for ensuring the efficacy and safety of drugs and medical devices. Before the FDA existed, drug makers could hawk any potion, claim treatment of any ailment, and make any promise on a label. But, throughout the twentieth century, the government was forced to take increasing action when children were poisoned by contaminated diphtheria and smallpox vaccines, an early antibiotic contained antifreeze, a drug prescribed for morning sickness in pregnancy caused babies to be born disfigured, and access to AIDS drugs was limited to a few clinical trials while thousands died. Sekeres describes all these events against the backdrop of the contentious 2011 hearings on the breast cancer drug Avastin, in which he participated as a panel member. The Avastin hearings, he says, put to the test a century of the FDA's evolution, demonstrating how its system of checks and balances works—or doesn't work.
...More
Book
Daemmrich, Arthur;
Radin, Joanna;
(2007)
Perspectives on Risk and Regulation: The FDA at 100
(/isis/citation/CBB000930536/)
Article
Tobbell, Dominique A.;
(2008)
Allied against Reform: Pharmaceutical Industry--Academic Physician Relations in the United States, 1945--1970
(/isis/citation/CBB000930716/)
Book
Hilts, Peter J.;
(2003)
Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation
(/isis/citation/CBB000502240/)
Article
Jessica Epstein;
(2018)
Drugs that Shaped the FDA: From Elixir Sulfanilamide to Thalidome
(/isis/citation/CBB942814659/)
Article
Daemmrich, Arthur;
(2007)
Pharmacovigilance and the Missing Denominator: The Changing Context of Pharmaceutical Risk Mitigation.
(/isis/citation/CBB000932013/)
Book
Shorter, Edward;
(2009)
Before Prozac: The Troubled History of Mood Disorders in Psychiatry
(/isis/citation/CBB000952059/)
Book
Gregory B. Jaczko;
(2019)
Confessions of a Rogue Nuclear Regulator
(/isis/citation/CBB130164448/)
Chapter
Daemmrich, A.;
Greene, J.;
(2010)
From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance
(/isis/citation/CBB001221031/)
Article
Daemmrich, A.;
(2007)
Pharmaceutical Regulation in the United States and Europe
(/isis/citation/CBB001221028/)
Book
David Demortain;
(2020)
The Science of Bureaucracy: Risk Decision-Making and the US Environmental Protection Agency
(/isis/citation/CBB170498113/)
Thesis
Schwartz, Jason Lee;
(2012)
External Factors: Advisory Committees, Regulation, and American Public Health, 1962--1999
(/isis/citation/CBB001567388/)
Article
Margaret E. MacDonald;
(March 2021)
Misoprostol: The Social Life of a Life-saving Drug in Global Maternal Health
(/isis/citation/CBB680292467/)
Book
Gaudillière, Jean-Paul;
Hess, Volker;
(2008)
Ways of Regulating: Therapeutic Agents between Plants, Shops and Consulting Rooms
(/isis/citation/CBB001221032/)
Book
Greene, Jeremy A.;
Watkins, Elizabeth Siegel;
(2012)
Prescribed: Writing, Filling, Using, and Abusing the Prescription in Modern America
(/isis/citation/CBB001214574/)
Article
Daemmrich, Arthur;
(2003)
Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-Five Years of Drug Lag Debate
(/isis/citation/CBB000502224/)
Book
Hay, Amy M.;
(2021)
The Defoliation of America: Agent Orange Chemicals, Citizens, and Protests
(/isis/citation/CBB039979128/)
Article
Angus Law;
Graham Spinardi;
(2021)
Performing Expertise in Building Regulation: ‘Codespeak’ and Fire Safety Experts
(/isis/citation/CBB766276484/)
Book
Jeremy A. Greene;
Flurin Condrau;
Elizabeth Siegel Watkins;
(2016)
Therapeutic Revolutions: Pharmaceuticals and Social Change in the Twentieth Century
(/isis/citation/CBB659048867/)
Article
Kahn, Jonathan;
(2008)
Exploiting Race in Drug Development: BiDil's Interim Model of Pharmacogenomics
(/isis/citation/CBB000953517/)
Book
Weisker, Albrecht;
(2012)
Die Klinik, die Kur und die Königin: Geschichte der Parkinsontherapie in der Paracelsus-Elena-Klinik Kassel
(/isis/citation/CBB001213883/)
Be the first to comment!